Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.90
Change (%)0.00 (0.00%)
Volume0
Data as of 08/17/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/03/17T2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update
Sequential Quarterly Product Revenue Growth of 16.5% LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results for the second quarter ended June 30, 2017.    Second Quarter Business and Financial Performance Highlights: Second quarter product revenue was $735,000, a $584,000 increase from the second q... 
Printer Friendly Version
08/02/17T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 37th Annual Canaccord Genuity Growth Conference. The conference is being held August 9-10, 2017 at the InterContinental Hotel in Bosto... 
Printer Friendly Version
07/27/17T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member
LEXINGTON, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it will join the Antimicrobials Working Group (AWG) as its first diagnostic member. T2 Biosystems joins thirteen antimicrobials companies in their mission to combat drug resistant infections and spur life-saving innovations.   “Diagnostics play a vital role in providing the best possible... 
Printer Friendly Version
07/20/17T2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 second quarter financial and operational results after the market closes on Thursday, August 3, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, August 3, 2017, to disc... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com
(339) 970-2843

Data provided by Nasdaq. Minimum 15 minutes delayed.